In the present study, the protein expression of SKP2 was reduced by ezetimibe administration, providing a clue that ezetimibe may prevent the progression of NAFLD-related HCC through downregulation of SKP2 protein expression. This evidence concerns the gene SKP2 and hepatocellular carcinoma.